background
studi
evalu
immunogen
rel
protect
efficaci
one
dose
influenza
vaccin
without
oilinwat
emuls
base
adjuv
system
method
four
thousand
fortyeight
healthi
adult
age
year
random
receiv
one
dose
either
adjuv
split
virion
g
hemagglutinin
antigen
ha
nonadjuv
g
ha
vaccin
hemagglutin
inhibit
hi
antibodi
respons
evalu
vaccin
day
month
safeti
studi
vaccin
evalu
entir
studi
durat
result
day
studi
vaccin
induc
hi
immun
respons
meet
us
regulatori
criteria
subject
year
seroprotect
rate
spr
seroconvers
rate
scr
group
spr
scr
nonadjuv
group
year
age
spr
scr
group
spr
scr
nonadjuv
group
vaccin
induc
higher
hi
geometr
mean
titer
nonadjuv
vaccin
time
point
month
subject
year
age
vaccin
group
still
met
us
regulatori
criteria
spr
scr
group
spr
scr
nonadjuv
group
protect
efficaci
evalu
due
low
number
rtqpcrconfirm
influenza
case
month
seriou
advers
event
subject
nonadjuv
group
potenti
immun
mediat
diseas
nonadjuv
group
report
conclus
singl
dose
either
adjuv
nonadjuv
influenza
vaccin
induc
protect
hi
antibodi
level
strain
persist
month
year
popul
mass
immun
consid
effect
prophylact
method
mitig
influenza
pandemicassoci
morbid
mortal
due
novel
antigen
characterist
swineorigin
influenza
pandem
viru
influenza
season
influenza
vaccin
avail
time
pandem
unlik
confer
protect
novel
viru
world
health
organ
encourag
develop
use
adjuv
influenza
vaccin
aim
dosereduct
antigenspar
potenti
provid
broader
vaccin
efficaci
drift
strain
crossreact
immun
base
experi
develop
prepandem
influenza
vaccin
util
oilinwat
emuls
base
adjuv
system
welltoler
highli
immunogen
adult
influenza
vaccin
g
hemagglutinin
ha
content
develop
largescal
random
studi
subject
year
age
assess
whether
one
dose
g
ha
influenza
vaccin
elicit
immun
respons
met
us
european
regulatori
criteria
addit
noninferior
superior
vaccin
protect
efficaci
versu
nonadjuv
g
ha
influenza
vaccin
evalu
phase
iii
observerblind
random
studi
adult
year
age
enrol
across
center
us
canada
novemb
decemb
random
alloc
ratio
receiv
one
dose
either
monoval
g
ha
pandem
influenza
vaccin
nonadjuv
g
ha
pandem
influenza
vaccin
enrol
stratif
age
year
year
year
year
subject
studi
personnel
involv
evalu
end
point
blind
intervent
administ
doubl
blind
possibl
vaccin
prepar
requir
mix
antigen
two
vial
random
perform
use
central
internetbas
system
balanc
group
respect
center
age
strata
previou
season
influenza
vaccin
adult
exclud
enrol
histori
physicianconfirm
influenza
infect
vaccin
receiv
vaccin
season
influenza
vaccin
within
day
preced
studi
start
confirm
suspect
immunosuppress
immunodefici
condit
diagnos
undergo
treatment
cancer
andor
histori
allergicanaphylact
reaction
follow
previou
influenza
vaccin
addit
laboratori
screen
perform
exclud
result
outsid
protocolspecifi
normal
rang
follow
safeti
laboratori
paramet
test
evalu
particip
elig
hepat
aminotransferas
total
direct
bilirubin
alkalin
phosphatas
creatinin
serum
urea
nitrogen
hemoglobin
hematocrit
white
blood
cell
count
platelet
count
activ
surveil
influenzalik
infect
ili
defin
fever
f
new
worsen
myalgia
accompani
new
worsen
cough
sore
throat
done
studi
visit
biweekli
telephon
contact
day
month
initi
plan
administr
second
studi
vaccin
dose
addit
subject
instruct
contact
studi
site
develop
ili
symptom
studi
site
notifi
possibl
ili
episod
visit
nasal
throat
swab
sampl
collect
schedul
within
day
symptom
onset
initi
antimicrobialinfluenza
antivir
therapi
ili
episod
report
day
onset
swab
specimen
collect
written
inform
consent
obtain
subject
prior
conduct
studyrel
procedur
studi
conduct
accord
good
clinic
practic
guidelin
declar
helsinki
local
regul
studyrel
document
approv
institut
review
board
influenza
vaccin
monoval
inactiv
splitvirion
antigen
suspens
strain
adjuv
arepanrix
tm
trademark
glaxosmithklin
vaccin
administ
plain
antigen
viral
seed
vaccin
prepar
per
recommend
oilinwat
emuls
base
adjuv
system
contain
squalen
mg
per
dose
mg
polysorb
mg
influenza
vaccin
dose
prepar
mix
antigen
separ
multidos
vial
ml
assign
studi
vaccin
administ
deltoid
muscl
within
min
mix
antigen
adjuv
first
coprimari
object
studi
evalu
hi
antibodi
respons
day
vaccin
vaccin
group
base
center
biolog
evalu
research
cber
committe
medicin
product
human
use
chmp
criteria
pandem
influenza
vaccin
adult
least
rtqpcrconfirm
acalifornia
influenza
case
requir
evalu
second
coprimari
object
noninferior
protect
efficaci
follow
superior
three
rtqpcrconfirm
acalifornia
influenza
case
diagnos
studi
descript
analys
influenza
attack
rate
vaccin
efficaci
improv
vei
comput
ili
pneumonia
case
studi
also
assess
whether
nonadjuv
g
ha
influenza
vaccin
elicit
immun
respons
met
us
european
regulatori
criteria
day
vaccin
whether
criteria
met
either
studi
vaccin
day
small
subset
subject
day
month
hemagglutin
inhibit
hi
antibodi
level
serum
sampl
assess
glaxosmithklin
vaccin
central
laboratori
use
valid
inhous
assay
cutoff
use
chicken
erythrocyt
previous
describ
strain
use
antigen
strain
rtqpcr
perform
viral
rna
clinic
sampl
describ
previous
viral
load
valu
quantifi
sampl
consid
posit
measur
viral
load
equal
assay
cutoff
serum
sampl
collect
vaccin
day
day
subset
subject
month
assess
humor
immun
respons
clinic
chemistri
hematolog
assess
day
immunolog
assess
base
hi
antibodi
seroconvers
rate
scr
seroprotect
rate
spr
geometr
mean
fold
rise
gmfr
vaccin
homolog
strain
post
hoc
exploratori
analys
includ
assess
possibl
correl
hi
antibodi
respons
bodi
mass
index
bmi
previou
influenza
vaccin
histori
assess
perform
identifi
respiratori
virus
isol
swab
sampl
ili
case
use
xtag
respiratori
viral
panel
rvp
fast
assay
luminex
molecular
diagnost
inc
toronto
canada
subject
use
diari
card
record
solicit
local
gener
symptom
occur
within
day
follow
vaccin
unsolicit
advers
event
occur
within
day
follow
vaccin
potenti
immunemedi
diseas
pimd
subset
ae
includ
autoimmun
diseas
inflammatori
andor
neurolog
disord
maymay
autoimmun
etiolog
seriou
advers
event
sae
record
throughout
studi
period
intens
solicit
advers
event
except
fever
grade
scale
grade
interfer
normal
activ
grade
prevent
normal
activ
grade
red
swell
diamet
mm
grade
fever
temperatur
c
fever
grade
scale
grade
temperatur
c
base
clinic
judgment
investig
assess
whether
aessa
potenti
relatednot
relat
studi
vaccin
serum
sampl
analysi
clinic
safeti
laboratori
paramet
collect
day
follow
laboratori
paramet
test
hepat
aminotransferas
total
direct
bilirubin
alkalin
phosphatas
creatinin
serum
urea
nitrogen
hemoglobin
hematocrit
white
blood
cell
count
platelet
count
sampl
size
calcul
take
consider
coprimari
object
overal
evalu
subject
vei
evalu
two
treatment
group
account
dropout
rate
coprimari
object
estim
provid
power
meet
coprimari
object
assum
refer
sprscr
subject
year
year
age
respect
vaccin
efficaci
nonadjuv
influenza
vaccin
attack
rate
subject
receiv
vaccin
pass
onesid
test
onesid
alpha
scr
spr
gmfr
incid
rate
solicit
unsolicit
advers
event
calcul
confid
interv
ci
analys
immunogen
perform
accord
protocol
atp
cohort
includ
evalu
subject
meet
elig
criteria
adher
protocoldefin
procedur
cox
regress
model
includ
vaccin
group
fix
effect
age
baselin
antibodi
titer
covari
use
estim
vei
ili
case
pneumonia
case
first
event
consid
multipl
event
report
subject
statist
analys
perform
use
statist
analysi
softwar
sa
version
total
subject
screen
receiv
vaccin
complet
studi
day
reason
withdraw
elimin
subject
analys
differ
time
point
present
fig
mean
age
subject
tvc
time
vaccin
year
age
group
year
rang
year
year
age
group
year
rang
year
overal
subject
respect
two
age
group
femal
major
subject
caucasian
respect
coprimari
object
first
coprimari
object
met
singl
dose
g
ha
influenza
vaccin
elicit
hi
immun
respons
year
year
age
group
met
cber
regulatori
criteria
day
tabl
chmp
criteria
met
year
year
age
group
data
present
second
coprimari
object
evalu
three
rtqpcrconfirm
acalifornia
influenza
case
identifi
nonadjuv
secondari
object
day
subset
n
receiv
g
ha
influenza
vaccin
cber
criteria
met
year
age
group
year
age
group
tabl
day
month
cber
criteria
met
subject
year
age
tabl
subject
year
age
ci
spr
thu
fulfil
cber
criteria
time
point
day
singl
dose
nonadjuv
g
ha
influenza
vaccin
elicit
hi
immun
respons
subject
year
year
age
met
cber
regulatori
criteria
tabl
year
age
group
met
cber
criteria
day
day
month
time
point
subject
year
age
ll
ci
spr
respect
ll
ci
scr
respect
thu
fulfil
cber
criteria
chmp
criteria
met
day
day
year
year
age
group
studi
vaccin
day
chmp
criteria
met
year
age
group
year
age
group
studi
vaccin
data
present
hi
antibodi
gmt
age
group
higher
postvaccin
time
point
receiv
influenza
vaccin
compar
receiv
nonadjuv
vaccin
gmt
gener
lower
year
compar
year
age
group
time
point
tabl
persist
hi
antibodi
respons
day
month
observ
studi
vaccin
although
lower
level
compar
observ
day
tabl
overal
immun
respons
vaccin
homolog
strain
appear
decreas
advanc
age
fig
webappendix
tabl
post
hoc
exploratori
analys
show
hi
antibodi
respons
mostli
compar
across
healthi
weight
overweight
obes
subject
clear
pattern
emerg
due
modest
number
subject
underweight
categori
webappendix
tabl
higher
hi
antibodi
observ
among
influenza
subject
compar
previou
season
influenza
vaccin
term
hi
antibodi
gmt
gmfr
webappendix
tabl
nonadjuv
treatment
group
report
sampl
studi
sampl
test
three
case
confirm
rtqpcr
one
two
case
respect
incid
ili
case
compar
two
treatment
group
except
day
respiratori
virus
rhinoviru
identifi
nasopharyng
swab
frequent
determin
respiratori
viru
tabl
solicit
advers
event
pain
inject
site
frequent
report
solicit
local
advers
event
report
subject
year
age
group
receiv
nonadjuv
influenza
vaccin
respect
p
subject
year
group
receiv
adjuv
nonadjuv
influenza
vaccin
respect
p
fig
webappendix
tabl
addit
age
group
statist
signific
higher
percentag
subject
receiv
adjuv
vaccin
report
red
swell
compar
nonadjuv
vaccin
group
p
muscl
ach
year
p
year
p
fatigu
year
p
year
p
headach
year
p
year
p
frequent
report
solicit
gener
advers
event
fig
webappendix
tabl
year
age
group
higher
percentag
subject
receiv
adjuv
vaccin
report
joint
pain
shiver
sweat
compar
nonadjuv
group
p
year
group
joint
pain
report
higher
percentag
subject
receiv
adjuv
vaccin
compar
subject
receiv
nonadjuv
vaccin
p
age
group
statist
signific
differ
observ
vaccin
group
term
shiver
sweat
fever
p
solicit
local
gener
advers
event
grade
intens
report
subject
year
age
group
incid
pain
inject
site
joint
pain
muscl
ach
grade
intens
significantli
higher
adjuv
vaccin
group
compar
nonadjuv
group
p
pain
inject
site
p
joint
pain
p
muscl
ach
incid
solicit
symptom
grade
intens
age
group
well
year
age
group
statist
signific
differ
adjuv
nonadjuv
vaccin
group
p
report
solicit
advers
event
higher
year
age
group
unsolicit
advers
event
total
subject
tabl
subject
treatment
group
year
year
subject
nonadjuv
treatment
group
year
year
two
event
intestin
obstruct
treatment
group
multipl
sclerosi
nonadjuv
treatment
group
consid
investig
possibl
relat
studi
vaccin
also
consid
pimd
day
month
pimd
accord
predefin
list
pimd
prefer
term
report
nonadjuv
influenza
treatment
group
respect
seven
fatal
sae
report
nonadjuv
treatment
group
respect
assess
investig
relat
vaccin
detail
descript
fatal
sae
provid
web
appendix
tabl
overal
sampl
laboratori
valu
hematolog
biochem
paramet
outsid
normal
laboratori
refer
rang
day
subject
adjuv
vaccin
group
subject
nonadjuv
vaccin
group
data
larg
control
studi
adult
year
age
older
demonstr
singl
dose
nonadjuv
influenza
vaccin
elicit
strong
hi
immun
respons
day
later
met
chmp
stringent
cber
criteria
pandem
influenza
vaccin
hi
antibodi
respons
persist
six
month
vaccin
vaccin
although
cber
criteria
met
year
age
group
chmp
criteria
year
age
group
coprimari
object
concern
rel
vaccin
efficaci
influenza
evalu
due
small
number
rtqpcrconfirm
influenza
case
low
number
case
observ
may
partial
due
time
studi
start
studi
vaccin
follow
peak
viru
transmiss
us
canada
week
last
week
octob
time
circul
diminish
consider
publish
estim
influenza
vaccin
effect
influenza
rang
overal
incid
ili
case
compar
two
group
except
first
day
vaccin
versu
ili
case
nonadjuv
treatment
group
respect
studi
suffici
power
detect
statist
signific
analysi
data
elderli
subject
present
studi
agreement
observ
made
previou
studi
one
dose
g
ha
influenza
vaccin
may
insuffici
meet
cber
criteria
month
elderli
two
dose
vaccin
administ
day
apart
induc
longterm
persist
hi
antibodi
put
protect
level
nicholson
et
al
demonstr
two
dose
differ
influenza
vaccin
elicit
hi
immun
respons
persist
seroprotect
level
subject
year
age
six
month
vaccin
although
lower
level
compar
younger
adult
p
similar
observ
result
show
previou
season
vaccin
appear
neg
influenc
strength
immun
respons
elicit
influenza
vaccin
especi
term
longterm
immunogen
conflict
report
whether
previou
season
influenza
vaccin
increas
risk
subsequ
contract
infect
requir
medic
attent
effect
bmi
immun
respons
also
studi
consist
previou
trial
present
studi
high
bmi
appear
impair
hi
antibodi
respons
shortli
vaccin
howev
sheridan
et
al
report
decreas
hi
antibodi
titer
obes
subject
month
vaccin
observ
also
made
present
studi
reactogen
safeti
profil
agreement
avail
data
adult
children
frequenc
solicit
local
advers
event
studi
higher
versu
nonadjuv
treatment
group
frequenc
solicit
advers
event
compar
lower
year
age
group
previou
clinic
trial
influenza
vaccin
compar
safeti
outcom
adjuv
nonadjuv
vaccin
report
similar
observ
higher
frequenc
local
gener
advers
event
adjuv
vaccin
compar
nonadjuv
vaccin
studi
observ
differ
two
vaccin
group
term
sae
consid
possibl
relat
vaccin
group
although
imbal
number
fatal
sae
observ
adjuv
nonadjuv
group
versu
none
consid
relat
vaccin
occur
subject
relev
medic
histori
gradual
decrement
hi
antibodi
gmt
elicit
studi
vaccin
vaccin
strain
older
subject
observ
could
attribut
immunosenesc
decreas
trend
advanc
age
also
observ
frequenc
solicit
advers
event
possibl
limit
studi
absenc
blood
sampl
collect
assess
immun
respons
day
month
period
six
month
anticip
cover
period
transmiss
influenza
viru
one
season
recent
publish
studi
enrol
subject
random
receiv
one
two
dose
adjuv
vaccin
follow
month
show
regulatori
criteria
met
month
administr
last
vaccin
dose
subject
age
year
receiv
either
one
two
vaccin
dose
subject
age
year
receiv
two
vaccin
dose
day
month
regulatori
criteria
still
met
subject
age
year
receiv
two
vaccin
dose
conclus
singl
dose
either
adjuv
nonadjuv
influenza
vaccin
elicit
protect
level
hi
antibodi
vaccin
homolog
strain
persist
day
month
year
popul
adjuvant
potenti
offer
opportun
antigenspar
make
influenza
vaccin
candid
help
meet
demand
larg
number
vaccin
dose
requir
mitig
pandem
influenza
carolin
gesualdi
clinic
studi
manag
janin
linden
prepar
studi
protocol
relat
studi
document
dorothi
slavin
clinic
safeti
repres
rosalia
calamera
clinic
data
coordin
karl
walraven
lab
manag
clinic
readout
final
thank
avishek
pal
glaxosmithklin
vaccin
adriana
rusu
xpe
pharma
scienc
provid
medic
write
servic
dr
santosh
mysor
xpe
pharma
scienc
co
glaxosmithklin
vaccin
editori
assist
manuscript
coordin
financi
disclosur
studi
fund
us
depart
health
human
servic
hh
assist
secretari
prepared
respons
aspr
biomed
advanc
research
develop
author
barda
glaxosmithklin
biolog
sa
glaxosmithklin
biolog
sa
involv
stage
studi
conduct
analysi
glaxosmithklin
biolog
sa
also
took
charg
cost
associ
develop
publish
present
manuscript
author
full
access
data
correspond
author
final
respons
submit
public
conflict
interest
investig
receiv
compens
studi
involv
travel
relat
studi
ping
li
miguel
madariaga
olivi
godeaux
david
vaughn
arewer
employe
glaxosmithklin
group
compani
report
receiv
restrict
share
compani
contributorship
wy
md
mk
na
contribut
data
collect
data
interpret
critic
review
manuscript
draft
pl
mm
og
dwv
contribut
studi
design
data
analysi
interpret
well
critic
review
draft
manuscript
trade
mark
statement
arepanrix
trade
mark
glaxosmithklin
group
compani
supplementari
data
associ
articl
found
onlin
version
http
